Nine-valent HPV vaccine is used to prevent precancerous lesions or atypical lesions such as cervical cancer caused by human papillomavirus, which can prevent 92. 1% of cervical cancer. Vaccination is primary prevention and screening is secondary prevention, both of which are equally important at present. Therefore, screening measures for cervical cancer cannot be relaxed because of vaccination.
On April 28th, 20 18, the State Administration of Pharmaceutical Products approved the marketing of the nine-valent human papillomavirus vaccine for preventing cervical cancer. From 2065438 to July 2008, the nine-valent HPV vaccine was listed in Guangdong. On August 16, Shenzhen's first 9-valent HPV vaccine was officially vaccinated in Luohu Adult Vaccination Clinic. In September, Beijing launched an appointment for a nine-valent cervical cancer vaccine.
Nine-valent cervical cancer vaccine has good immunogenicity. After three doses of inoculation, the seroconversion rate of related types of serum antibodies can almost reach 100%. After vaccination 1 month, the peak geometric average titer of antibody can reach 100 times of the antibody level after natural infection, and this value will drop to 10 times in the next two months, and will remain in the platform period. The antibody level of the vaccine can be maintained for at least 4 years. In the clinical trial of the curative effect of nine-valent cervical cancer vaccine, the main observation focuses on the persistent infection of related human papillomavirus type, genital warts of related human papillomavirus type, cervical intraepithelial neoplasia (CIN), external genital or vaginal intraepithelial neoplasia (VIN or VaIN). Clinical trials show that vaccination with nine-valent cervical cancer vaccine can produce good protective effect, effectively reduce the persistent infection and precancerous lesions of human papillomavirus in cervix, vagina and external genitalia, and the protective effect can reach more than 90%. Nine-valent cervical cancer vaccine contains human papillomavirus -6 and human papillomavirus-1 1 VLP, which has a good preventive effect on genital warts.
The nine-valent cervical cancer vaccine approved for marketing in China is suitable for women aged 16 ~26. The reason for this age group is from three aspects:
1. Clinical trials supporting the marketing of this vaccine include1women aged 6-26. At this age, the data of overseas clinical research and the protective effect of vaccines on persistent infection in East Asian people show that the advantages outweigh the disadvantages.
2. The probability of having sex with girls aged 9 ~ 15 in China is very low. Vaccinators aged 9 ~ 15 only carried out immune bridging test, and the clinical research data of East Asian Chinese population in this test were limited.
3. Women over the age of 26 may have a history of virus exposure and infection, but there is no evidence to prove that this vaccine has a protective effect on exposed people of this age.